Literature DB >> 32810215

Improved relapse recovery in paediatric compared to adult multiple sclerosis.

Tanuja Chitnis1,2, Greg Aaen3, Anita Belman4, Leslie Benson5, Mark Gorman5, Manu S Goyal6, Jennifer S Graves7, Yolanda Harris8, Lauren Krupp4, Timothy Lotze9, Soe Mar6, Jayne Ness8, Mary Rensel10, Teri Schreiner11, Jan-Mendelt Tillema12, Emmanuelle Waubant13, Bianca Weinstock-Guttman14, Shelly Roalstad15, John Rose15, Howard L Weiner2,16, T Charles Casper15, Moses Rodriguez12.   

Abstract

Incomplete relapse recovery contributes to disability accrual and earlier onset of secondary progressive multiple sclerosis. We sought to investigate the effect of age on relapse recovery. We identified patients with multiple sclerosis from two longitudinal prospective studies, with an Expanded Disability Status Scale (EDSS) score within 30 days after onset of an attack, and follow-up EDSS 6 months after attack. Adult patients with multiple sclerosis (n = 632) were identified from the Comprehensive Longitudinal Investigations in Multiple Sclerosis at Brigham study (CLIMB), and paediatric patients (n = 132) from the US Network of Paediatric Multiple Sclerosis Centers (NPMSC) registry. Change in EDSS was defined as the difference in EDSS between attack and follow-up. Change in EDSS at follow-up compared to baseline was significantly lower in children compared to adults (P = 0.001), as were several functional system scores. Stratification by decade at onset for change in EDSS versus age found for every 10 years of age, EDSS recovery is reduced by 0.15 points (P < 0.0001). A larger proportion of children versus adults demonstrated improvement in EDSS following an attack (P = 0.006). For every 10 years of age, odds of EDSS not improving increase by 1.33 times (P < 0.0001). Younger age is associated with improved recovery from relapses. Age-related mechanisms may provide novel therapeutic targets for disability accrual in multiple sclerosis.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  clinical practice; epidemiology; multiple sclerosis; vision; white matter lesion

Year:  2020        PMID: 32810215     DOI: 10.1093/brain/awaa199

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  10 in total

1.  Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.

Authors:  Maria Gontika; Charalampos Skarlis; Nikolaos Markoglou; Maria-Eleftheria Evangelopoulos; George Velonakis; George P Chrousos; Marinos Dalakas; Leonidas Stefanis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2021-10-01       Impact factor: 3.307

2.  Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations.

Authors:  Andrew J Solomon; Georgina Arrambide; Wallace Brownlee; Anne H Cross; María I Gaitan; Fred D Lublin; Naila Makhani; Ellen M Mowry; Daniel S Reich; Àlex Rovira; Brian G Weinshenker; Jeffrey A Cohen
Journal:  Neurol Clin Pract       Date:  2022-06

3.  First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center.

Authors:  Charalampos Skarlis; Nikolaos Markoglou; Maria Gontika; Anastasia Bougea; Serafeim Katsavos; Artemios Artemiadis; George Chrousos; Marinos Dalakas; Leonidas Stefanis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2022-10-05       Impact factor: 3.830

4.  Enhancing Mood, Cognition, and Quality of Life in Pediatric Multiple Sclerosis.

Authors:  Cristina Fernandez-Carbonell; Leigh E Charvet; Lauren B Krupp
Journal:  Paediatr Drugs       Date:  2021-05-17       Impact factor: 3.022

5.  Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

Authors:  Omar A Abdel-Mannan; Celeste Manchoon; Thomas Rossor; Justine-Clair Southin; Carmen Tur; Wallace Brownlee; Susan Byrne; Manali Chitre; Alasdair Coles; Rob Forsyth; Rachel Kneen; Kshitij Mankad; Dipak Ram; Siobhan West; Sukhvir Wright; Evangeline Wassmer; Ming Lim; Olga Ciccarelli; Cheryl Hemingway; Yael Hacohen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-21

Review 6.  Preventing Multiple Sclerosis: The Pediatric Perspective.

Authors:  Duriel Hardy; Tanuja Chitnis; Emmanuelle Waubant; Brenda Banwell
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

Review 7.  Cognitive Issues in Pediatric Multiple Sclerosis.

Authors:  Emilio Portaccio; Ermelinda De Meo; Angelo Bellinvia; Maria Pia Amato
Journal:  Brain Sci       Date:  2021-03-30

8.  Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?

Authors:  Joachim Havla; Thivya Pakeerathan; Kevin Rostasy; Ilya Ayzenberg; Carolin Schwake; Jeffrey L Bennett; Ingo Kleiter; Ana Felipe-Rucián; Stephanie C Joachim; Amelie S Lotz-Havla; Tania Kümpfel; Markus Krumbholz; Eva M Wendel; Markus Reindl; Charlotte Thiels; Thomas Lücke; Kerstin Hellwig; Ralf Gold
Journal:  J Neuroinflammation       Date:  2021-05-29       Impact factor: 8.322

Review 9.  Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.

Authors:  Dejan Jakimovski; Samreen Awan; Svetlana P Eckert; Osman Farooq; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2021-12-23       Impact factor: 5.749

10.  How patients with multiple sclerosis acquire disability.

Authors:  Fred D Lublin; Dieter A Häring; Habib Ganjgahi; Alex Ocampo; Farhad Hatami; Jelena Čuklina; Piet Aarden; Frank Dahlke; Douglas L Arnold; Heinz Wiendl; Tanuja Chitnis; Thomas E Nichols; Bernd C Kieseier; Robert A Bermel
Journal:  Brain       Date:  2022-09-14       Impact factor: 15.255

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.